Skip to main content
. 2021 Feb 22;21:157. doi: 10.1186/s12884-021-03612-z

Fig. 3.

Fig. 3

Cost-effectiveness acceptability curves in 2019 United States dollars (US$). The left panel is in comparison to the vaccine only strategy while the right panel is compared to the TDF after HBeAg test strategy. HBeAg, hepatitis B envelope antigen; TDF, Tenofovir Disoproxil Fumarate